RE:RE:RE:RE:RE:New Press Release - COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Resultslscfa wrote: I think the one-time merger expenses were included in q1 SG&A for CZO and AEZS and the $3M US is the new recurring level of SG&A. Fire someone.
| | CZO | AEZS | Total |
| Q1 24 | | | |
| SGA cdn | 2,234 | | |
| Fx rate | 1.3488 | | |
| SGA USD | 1,656 | 3,514 | 5,170 |
| | | | |
| Q2 24 | | | 3,044 |
The merger wasn't completed until Jun. 6 or basically the end of the quarter. The TSX-V listing expenses will fall off. Human resources can be streamlined. They only need one CFO for instance. There are fewer member of the Board of Directors to pay at the combined company. Some operations could be consolidated. The cost of the diagnostic trial is over and the diagnostic is set to become a potential cashcow. They are conducting a portfolio review and could halt development of some programs to prioritize the most promising. They have been looking at potentially partnering programs. They are conducting a reveiw of their programs and expect to release more details "shortly" for their forward plans.